Figure 6B illustrates a Sankey plot representing 11 clinical trial events where small molecules were involved in early-stage phases (I and II) and late-stage phases (III and IV) for thyroid cancer. These trials involve three targetable proteins (including BRAF, RET, and EPHA7), and 9 small molecule drugs with 5 mechanisms of action. Dabrafenib, vemurafenib, and encorafenib were RAF inhibitors, sorafenib and sunitinib were FLT3 inhibitors, regorafenib was an FGFR inhibitor, vandetanib was an EGFR inhibitor, and pralsetinib and selpercatinib were RET inhibitors (Supplementary Table S11). This evidence concerns the gene EPHA7 and thyroid gland carcinoma.